Issue Date: April 30, 2012
Amgen To Acquire Turkish Drug Firm
Amgen has agreed to pay $700 million for Turkey-based Mustafa Nevzat Pharmaceuticals. Privately held Mustafa Nevzat, which had sales of roughly $200 million in 2011, is a leading supplier of drugs to Turkish hospitals. Like many of its big pharma competitors, Amgen has been pushing into emerging markets; last year, it paid $215 million for the Brazilian generic drug firm Bergamo. Amgen established a Turkish affiliate in 2010 that markets two products in the country.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society